Table III.
Prevalence and titers of CD4i-neutralizing antibodies against HIV-27312A/V434M in plasma of HIV-1–infected subjects
| CD4i Nab titersa
|
|||||
|---|---|---|---|---|---|
| HIV-1 plasma | n | Positive | Mean | SD | Median |
| (%) | |||||
| Clade A | 39 | 35 (90) | 0.0029 | 0.0052 | 0.0007 |
| Clade B | 25 | 24 (96) | 0.0047 | 0.0105 | 0.0003 |
| Clade C | 23 | 22 (96) | 0.0051 | 0.0118 | 0.0004 |
| Clade D | 7 | 7 (100) | 0.00007 | 0.00006 | 0.00007 |
| Clade F | 6 | 5 (83) | 0.0008 | 0.0005 | 0.001 |
| Clade G | 5 | 3 (60) | 0.0061 | 0.0092 | 0.0015 |
| Clade H | 2 | 2 (100) | 0.002 | 0.0028 | 0.002 |
| CRF01 | 1 | 1 (100) | 0.0003 | – | 0.0003 |
| CRF02 | 77 | 72 (94) | 0.0053 | 0.0106 | 0.0008 |
| CRF11 | 4 | 3 (75) | 0.00005 | 0.00002 | 0.00004 |
| Total | 189 | 174 (92) | 0.004 | 0.0093 | 0.0004 |
Reciprocal IC50 titers of CD4i-neutralizing antibodies against HIV-27312A/V434M pretreated with 15 nM sCD4.